MedTrace Logo

Bioequivalence Between Two Tablet Formulations Of Doxycycline Carragenate

NCT00939562 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2009-12-23

Study results available
· View outcomes & findings →

Summary

The purpose of this protocol is to study if two different tablet formulations of doxycycline are bioequivalent to each other.

Conditions

Interventions

DRUG

doxycycline monohydrate tablet

Tablet, 100 mg, Single dose

DRUG

doxycycline carragenate tablet

Tablet, 100 mg, Single dose

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00939562 on ClinicalTrials.gov